Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood collection: Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.

Study summary

Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.

Eligibility

Primary outcome measure(s)

• Plasma tryptophan levels — Baseline
  Variation in plasma tryptophan levels between triptan-resistant and triptan-responsive migraine patients.

Trial sites (1)

More University Hospital, Clermont-Ferrand trials in France

Other trials for the same condition